

Original Article

Honey Bee Dry Venom Reduces Hepatitis B Virus Surface Antigen Secretion in PLC/PRF/5 Cell Line

Hussein Khani ¹M.Sc., Mahdi Ghorbani ^{1*}Ph.D., Farshad Nojoomi ²Ph.D.
Alireza Mohebbi ²M.Sc.

¹Department of Medical Laboratory Sciences, AJA University of Medical Sciences, Tehran, Iran.

²Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.

ABSTRACT

Article history

Received 20 May 2019

Accepted 22 Jul 2019

Available online 10 Dec 2019

Key words

Anti-HBsAg

Bee venom

Chronic HBV infection

Natural product

Background and Aims: Currently, many efforts are directed toward functional Hepatitis B virus (HBV) treatment. This is achievable by suppression of HBV surface antigen (HBsAg) secretion. In this regard, use of natural products has been the areas of interest by scientific communities.

Materials and Methods: Dried Honey Bee venom was extracted for assessing its anti-HBsAg secretion potential. Hepatoma cell-derived PLC/PRF/5 was propagated in complete medium. The cell line was treated by a serial dilution of Bee venom. Cell cytotoxicity (IC₅₀) was measured by MTT colorimetric assay at three post-treatment times. HBsAg secretion was evaluated from PLC/PRF/5 supernatant treated by under-cytotoxic concentrations of Bee venom by using enzyme-linked immunosorbent assay.

Results: The results indicated that dried Bee venom extract is able to reduce secretion of HBsAg from the cell line with Selectivity Index (SI) of eight. Reduced levels of HBsAg were in dose-dependent manner and it was in its lower concentrations at 8 ppm after 12 hr post treatment. The IC₅₀ was observed to be 63.78 ppm.

Conclusions: The Bee venom has anti-HBV activity. The way we used under-cytotoxic concentration of Bee venom, the HBsAg secretion was restored after 24 hr post treatment. Furthermore, mechanism of action of Bee venom in reducing HBsAg level needs to be further investigated.

Introduction

The human hepatitis B virus (HBV) is a major etiological factor for causing chronic hepatitis (CHB) and consequently cirrhosis and hepatocellular carcinoma (HCC) [1–3]. There are over 250 million chronically infected people worldwide, and annually 600,000 death cases occur each year from HBV-related organ failure [4]. In order to reduce the risk of HCC and mortality, some Food and Drug Administration approved nucleos(t)ide analogues are recommended including lamivudine, adefovir, entecavir, telbivudine, and tenofovir that suppress or reduce viral replication [5]. The inhibitory effects of anti-HBV drugs are only transient because of the viral scape mutants. Furthermore, the drug only retains their antiviral abilities when they are used for a long treatment course. A functional cure for CHB is known by suppressing HBV surface antigen (HBsAg) secretion inhibition [4]. There are several significant approaches regarding HBsAg secretion inhibition. Recent advances in anti-HBV research has been around nucleic acid polymers [6]. Nucleic acid polymers block the release of HBsAg from infected hepatocytes by the selective targeting of the assembly and/or secretion of subviral particles [7]. There has been an approach for gene silencing human trial by using small interfering RNAs (siRNAs), and not completed due to integrated form of HBV in residual hepatocytes [8]. Further research in these approaches is still ongoing. Nature is a vast source of substances for discovering active products acting against human pathogens [9,10]. In this regard, Honey

Bee (*Apis mellifera*) venom is known to have therapeutics potential for treatment of viral infections and cancer [11–15]. The major components of bee venom dry matter is peptides (>50%) and proteins (10-14%) [16]. About 40-50% of the venom peptides is comprised of a basic polypeptide named Melittin, which has the main therapeutic potential of the venom dry matter [14,17]. Wachinger et al have reported inhibitory effect of Melittin on human immuno-deficiency virus 1 replication. Their results indicated that Melittin is able to decrease human immunodeficiency virus 1 mRNAs in a dose-dependent manner [18]. This study aimed to investigate whether dry bee venom containing Melittin would influence release of HBsAg from the PLC/PRF/5 cell line containing integrated viral genome.

Materials and Methods

Preparation of honey bee crowd extract

Genuine bee venom was collected through the sting following mechanical stimulation. Hives containing *Apis Mellifera* colonies were hired from Tabriz province, Iran. Each colony was 'milked' for 5 minutes using a 12-V wet-cell battery in conjunction with a converter (12 V DC to 115 V AC). An electrical timer was used to break the circuit for 4 sec at 3-sec intervals. An average of 20 beehives must be milked in this way to obtain 1 g of venom. 1 µg/ml (1 ppm) dry extract was dissolved in Dimethyl sulfoxide (DMSO) and a serial dilution in the range of 1 to 128 ppm was provided.

Cell culture of PLC/PRF/5

PLC/PRF/5 was provided from the previous study of our group [19]. A complete medium containing DMSO (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and 1% Pen/Strep (Gibco, USA) antibiotics was prepared for cell culture. A vial stock of the cell line was melted and propagated on T-75 flasks and incubated at 37°C with 5% CO₂ and 10% humidity. After achieving a >90% confluency, cells were harvested and seeded into 96-well plates supplemented with complete medium for cell cytotoxicity assay.

Cell viability and cytotoxicity assay

PLC/PRF/5 cells were seeded either with complete medium or medium containing honey bee crowd extracts. Briefly, 8000-10,000 cells/well were seeded and incubated for 12 hr. After that, supernatants were removed and replaced with either fresh complete medium or extracts. Cell viability was assessed for 12 hr, 48 hr, and 72 hr post-treatment with MTT assay (Sigma, USA). MTT was prepared in 5 mg/ml stocks. After each time-point, wells were washed in phosphate buffered saline (Gibco, USA) and MTT was added (20 µl/well). After reduction of MTT and formation of violet Formazan crystals, DMSO was added to each well (100 µl/well). The plates were read at 570 nm with the enzyme-linked immunosorbent assay (ELISA)-reader (Bio Teck, Lionheart Technologies, Inc., USA). Each test was assessed in triplicate.

Investigation of HBsAg secretion

For HBsAg secretion inhibition, 8000-10,000 cells were seeded into each well in duplicate. 12 hr cells were washed in phosphate buffered

saline and replaced with either complete medium or medium containing venom dry extracts. Concentrations below cell cytotoxicity were used for the assay. Supernatants were collected and kept in -20°C after 12 hr, 48 hr, and 72 hr post treatment for ELISA. HBsAg Sandwich ELISA kit (PadTan Danesh Co., Tehran, Iran) was used to detect HBsAg in the supernatant according to the manufacture protocol. The plates were read at 450 nm with ELISA-reader (Bio Teck, Lionheart Technologies, Inc., USA). Cut-off value was 0.2 and result was calculated with the following formula:

$$S/Co = \frac{\text{Sample OD}}{\text{Cut-off value}}$$

S/Co values more than 1 was considered as positive. Optical densities for each test were also evaluated for assessing HBsAg reduction levels in supernatant. The study was conducted in accordance with Declaration of Helsinki for Human Research and the proposal was approved by the university Ethics Committee at AJA University of Medical Sciences.

Statistical analyzes

Statistical analyses were performed with two-way ANOVA with GraphPad Prism 7. Graphs were drawn by using MS-Excel 2016.

Results**Honey bee dry extracts TCID₅₀**

Tissue culture infectious dose 50 (TCID₅₀) was obtained as high as 63.78 at 12 hr post treatment. No significant toxicity was observed at 12 hr post treatment. At higher concentrations, only 64 ppm and 128 ppm had 83% and 86% cytotoxicity, respectively (Fig.

1). Four concentrations (1 ppm, 2 ppm, 4 ppm, and 8 ppm) with very low cytotoxicity were chosen for investigations HBsAg secretion in PLC/PRF/5 cell line.

However, using lower non-toxic concentrations lead to cell propagation. This allows restoration of HBsAg secretion. This is supported by the ELISA report (Fig. 2). As it

is illustrated, HBsAg secretion reduces at 12 hr post-treatment. Data showed HBsAg secretion being lowest amount in 8 ppm concentration of dried bee venom. There were no significant differences between concentrations 1 ppm and 2 ppm and concentrations 4 ppm and 8 ppm. The selectivity index was ~8 at 12 hr post-treatment.




Fig. 1. MTT assay showed not cytotoxicity at low bee venom concentrations.




Fig. 2. ELISA assay demonstrated that HBsAg secretion was reduced in a dose-dependent manner at 12 hr post treatment

Discussion

The results indicated that a low concentration of bee venom reduces secretion of HBsAg at early hours of post-treatment.

In our previous study, we have overviewed different classes of HBsAg secretion inhibitors [4]. Here, the effect of dried honey bee venom extract was applied for

investigating its effect on HBsAg secretion *in vitro*. Melittin is well known to have antiviral activities. Recently, a Melittin-like peptide has been used in the complex of siRNA, ARC-520 for liver targeting [8]. Primary liver carcinoma (PLC)-derived cell line (PLC/PRF/5) was reported containing integrated form of HBV divergent sequence of adw subtype [20, 21]. This cell line contains last fragment of HBV genome and therefore produces and secretes HBsAg but no other known viral protein [22].

Different therapeutic studies have been performed on PLC/PRF/5 to inhibit secretion of HBsAg. Varma et al. showed that herbal medicine, HD-03/ES is able to inhibit HBsAg transcription in PLC/PRF/5 cell line [23]. The presented results indicate the potential anti-HBsAg secretion effect of bee venom dry extract. Further studies are warranted for investigating its possible mechanism of action. In addition, the potential of bee

venom active ingredients on HBsAg secretion is needed to be assessed.

Conclusion

Here, it was found that dried extract of bee venom has anti-HBsAg secretion activity. Reduction of HBsAg was dose-dependent and it was in its lowest level at 8 ppm concentration of venom at 12 hr post-treatment. As we have used under-cytotoxic concentration of bee venom, the HBsAg secretion was restored after 24 hr post treatment. Furthermore, mechanism of action of bee venom in reducing HBsAg level need to be investigated in the future.

Conflict of Interest

The authors declare that there are not conflicts of interest.

Acknowledgements

This study was carried out as part of the research in collaboration between AJA University of Medical Sciences and Golestan University of Medical Sciences, Gorgan, Iran. AJA University of Medical Sciences, Tehran, Iran, provided the grant of this study.

References

- [1]. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterol.* 2009; 137(5): 1593-608.
- [2]. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. *Gut.* 2012; 61(S 1): 16-17.
- [3]. Mohebbi A, Mohammadi S, Memarian A. Prediction of HBF-0259 interactions with hepatitis B Virus receptors and surface antigen secretory factors. *Virus Dis.* 2016; 27(3): 234-241.
- [4]. Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An overview of hepatitis B virus surface antigen secretion inhibitors. *Front Microbiol.* 2018; 9(4): 19-26.
- [5]. Lim YS. Management of antiviral drug resistance in chronic hepatitis B. *World J Gastroenterol.* 2017; 11(2): 189-95.
- [6]. Vaillant A. Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection., *Antiviral Res.* 2016; 133(9): 32-40.
- [7]. Schöneweis K, Motter N, Roppert PL, Lu M, Wang B, Roehl I, et al. Activity of nucleic acid polymers in rodent models of HBV infection. *Antiviral Res.* 2018; 149(1): 26-33.
- [8]. Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JYN, et al. Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. *Clin Pharmacol Drug Dev.* 2017; 6(4): 350-62.
- [9]. Saleem M. Natural products as antimicrobial agents-an update. In: *Novel Antimicrobial Agents and Strategies.* Wiley Online Library; 2014.

- [10]. Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. *J Tradit Complement Med.* 2014; 4(1): 24-35.
- [11]. Zhang H, Zhao B, Huang C, Meng XM, Bian EB, Li J. Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocellular carcinoma HepG2 cells. *PLoS One* 2014; 9(5): 95520.
- [12]. Oršolić N. Bee venom in cancer therapy. *Cancer and Metastasis Reviews* 2012; 31(1-2):173-94.
- [13]. Uddin MB, Lee BH, Nikapitiya C, Kim JH, Kim TH, Lee HC, et al. Inhibitory effects of bee venom and its components against viruses in vitro and in vivo. *J Microbiol.* 2016; 54(12): 853-66.
- [14]. Uzair B, Bushra R, Khan BA, Zareen S, Fasim F. Potential uses of venom proteins in treatment of HIV. *Protein Pept Lett.* 2018; 25(7): 619-25.
- [15]. Picoli T, Peter CM, Vargas GD, Hübner SO, Lima M de, Fischer G. Antiviral and virucidal potential of melittin and apamin against bovine herpesvirus type 1 and bovine viral diarrhea virus. *Pesqui Vet Bras.* 2018; 38(4): 595-604.
- [16]. Bogdanov S. Royal jelly, bee brood: composition, health, medicine: a review. *Lipids.* 2011; 3(8): 8-19.
- [17]. Gajski G, Garaj-Vrhovac V. Melittin: A lytic peptide with anticancer properties. *Environmental Toxicol Pharmacol.* 2013; 36(2): 697-705.
- [18]. Wachinger M, Kleinschmidt A, Winder D, Von Pechmann N, Ludvigsen A, Neumann M, et al. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. *J Gen Virol.* 1998; 79(4): 731-40.
- [19]. Sheikh M, Eshraghi HR, Khoshnia M, Mazandarani M, Moradi A. Cytotoxic effect of capparid spinosa L. on the PLC/PRF/5 human hepatocellular carcinoma cell line. *Med Lab J.* 2017; 11(4): 9-12.
- [20]. Ziemer M, Garcia P, Shaul Y, Rutter WJ. Sequence of hepatitis B virus DNA incorporated into the genome of a human hepatoma cell line. *J Virol.* 1985; 53(3): 885-92.
- [21]. Koch S, von Loringhoven AF, Kahmann R, Hofschneider PH, Koshy R. The genetic organization of integrated hepatitis B virus DNA in the human hepatoma cell line PLC/PRF/5. *Nucl Acid Res.* 1984; 12(17): 6871-886.
- [22]. Chakraborty PR, Ruiz-opazo N, Shouval D, Shafritz DA. Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line. *Nature* 1980; 286(5772): 531.
- [23]. Varma SR, Sundaram R, Gopumadhavan S, Vidyashankar S, Patki PS. HD-03/ES: A herbal medicine inhibits hepatitis B surface antigen secretion in transfected human hepatocarcinoma PLC/PRF/5 cells. *Hepat Res Treat.* 2013; 2013(1): 125398.